1 hr. ago
Gossamer Bio has announced a private placement agreement valued at up to $250m, including $150m of committed capital intended to support the development and potential US Food and Drug Administration (FDA) approval of seralutinib.
Seralutinib is intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension ****** ociated with interstitial lung disease (PH-ILD).
The private investment comprises an initial closing, a subsequent closing contingent upon FDA acceptance of a new drug application (NDA) for seralutinib in PAH and warrants exercisable upon FDA approval.
The company plans to submit the NDA by September 2026. The proceeds will help advance seralutinib's clinical development and potential commercialisation, with net funds expected to sustain operations until 2028.
Gossamer recently regained global rights to seralutinib.
#Potential #approval
Seralutinib is intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension ****** ociated with interstitial lung disease (PH-ILD).
The private investment comprises an initial closing, a subsequent closing contingent upon FDA acceptance of a new drug application (NDA) for seralutinib in PAH and warrants exercisable upon FDA approval.
The company plans to submit the NDA by September 2026. The proceeds will help advance seralutinib's clinical development and potential commercialisation, with net funds expected to sustain operations until 2028.
Gossamer recently regained global rights to seralutinib.
#Potential #approval
2 hours ago
The Institute of Singapore Chartered Accountants (ISCA) and the Institute of Chartered Accountants of India (ICAI) have agreed to strengthen collaboration on initiatives covering AI training and professional qualification recognition.
Under the expanded collaboration, the ISCA signed a letter of cooperation for a proposed Global AI Fluency Initiative based on its AI Fluency Programme.
Subject to approvals and agreed implementation terms, the two accountancy bodies will provide practical and responsible AI learning to ICAI members and students.
The programme is expected to benefit the ICAI's more than 1.5 million members and students.
The approximately 30-hour programme includes 180 workplace-based cases covering AI foundations, accounting specialisations, and AI leadership and governance.
#institute #chartered #icai #fluency
Under the expanded collaboration, the ISCA signed a letter of cooperation for a proposed Global AI Fluency Initiative based on its AI Fluency Programme.
Subject to approvals and agreed implementation terms, the two accountancy bodies will provide practical and responsible AI learning to ICAI members and students.
The programme is expected to benefit the ICAI's more than 1.5 million members and students.
The approximately 30-hour programme includes 180 workplace-based cases covering AI foundations, accounting specialisations, and AI leadership and governance.
#institute #chartered #icai #fluency
2 hours ago
The Committee on Foreign Investment in the US (CFIUS) has launched a national security review of Shein's acquisition of clothing retailer Everlane, Bloomberg reported, citing unnamed sources.
The Treasury-led interagency panel began scrutinising the transaction after the $80m deal was finalised in May 2026.
Shein itself initiated the review process at that point—a departure from standard practice, since companies usually obtain CFIUS approval before a deal closes rather than afterwards.
The central question is whether Shein's ownership of a business holding US consumers' personal data poses a threat to national security.
No outcome has yet emerged from the review.
#everlane
The Treasury-led interagency panel began scrutinising the transaction after the $80m deal was finalised in May 2026.
Shein itself initiated the review process at that point—a departure from standard practice, since companies usually obtain CFIUS approval before a deal closes rather than afterwards.
The central question is whether Shein's ownership of a business holding US consumers' personal data poses a threat to national security.
No outcome has yet emerged from the review.
#everlane
2 hours ago
Exxon is in the running for Shell's U.S. chemicals business that could fetch $8 billion, the Financial Times reported today, citing unnamed sources familiar with developments.
The U.S. supermajor is competing with LyondellBasell, Apollo Global Management, and the Kuwait Petroleum Corporation, the unnamed sources also told the publication. The potential buyers have submitted non-binding offers to Shell, with these ranging from offers to buy parts of the business to offers for the whole division.
Shell's chemicals business in the United States comprises four facilities in Louisiana, Texas, and Pennsylvania that make chemicals used in a range of industries, from plastics production to detergents.
Shell has made two **** et sales recently, one of its onshore wind and solar power business in Europe and the other of a stake in a gas project offshore Cyprus. The wind and solar power deal went to TotalEnergies and involved 500 megawatts of combined renewable generation capacity in operation and in development, as well as a pipeline of projects for future development across Italy, the Netherlands, Spain, and the UK.
The transaction is subject to regulatory approvals and is expected to complete by the end of 2026, Shell said earlier this month in the announcement of the deal with TotalEnergies.
#business #chemicals #unnamed #wind
The U.S. supermajor is competing with LyondellBasell, Apollo Global Management, and the Kuwait Petroleum Corporation, the unnamed sources also told the publication. The potential buyers have submitted non-binding offers to Shell, with these ranging from offers to buy parts of the business to offers for the whole division.
Shell's chemicals business in the United States comprises four facilities in Louisiana, Texas, and Pennsylvania that make chemicals used in a range of industries, from plastics production to detergents.
Shell has made two **** et sales recently, one of its onshore wind and solar power business in Europe and the other of a stake in a gas project offshore Cyprus. The wind and solar power deal went to TotalEnergies and involved 500 megawatts of combined renewable generation capacity in operation and in development, as well as a pipeline of projects for future development across Italy, the Netherlands, Spain, and the UK.
The transaction is subject to regulatory approvals and is expected to complete by the end of 2026, Shell said earlier this month in the announcement of the deal with TotalEnergies.
#business #chemicals #unnamed #wind
4 hours ago
Tension at the Metropolitano after the boos aimed at Julián Álvarez headline a matchday in which FC Barcelona showed overwhelming dominance against Elche, Mourinho stepped in amid the 'Vinicius case', and Ligue 1 witnessed Ferran Torres' instant resurrection in Paris. On top of that, the transfer market is delivering dramatic twists just days before the deadline.
The atmosphere among the Atlético faithful is reaching boiling point. Atlético de Madrid fans showed strong disapproval toward Julián Álvarez after he made clear his intention to leave the club. After the final whistle against Villarreal, boos echoed around the stands, and the forward headed alone to the dressing room by decision of the club hierarchy to avoid further incidents.
The reigning champion kicked off LaLiga by laying down the law with an emphatic 0-5 win. In a brilliant attacking display, Raphinha and Fermín led the team with a brace each, joined by Adeyemi opening his account as a Barça scorer. A standout cameo from debutant Gordon in just 20 minutes put the finishing touch on an imposing start.
José Mourinho has spoken out after the controversial incidents in Cornellá. The Real Madrid coach publicly defended the Brazilian attacker, taking command within the Madrid dressing room and trying to ease the external pressure once again closing in on his biggest star.
He came, he saw, he conquered. Ferran Torres enjoyed a dream start in Ligue 1, rescuing PSG from the brink against Rennes. After trailing 0-2 at half-time, the Spanish forward took control in an extraordinary second half and scored a crucial brace to level the match.
#lvarez
The atmosphere among the Atlético faithful is reaching boiling point. Atlético de Madrid fans showed strong disapproval toward Julián Álvarez after he made clear his intention to leave the club. After the final whistle against Villarreal, boos echoed around the stands, and the forward headed alone to the dressing room by decision of the club hierarchy to avoid further incidents.
The reigning champion kicked off LaLiga by laying down the law with an emphatic 0-5 win. In a brilliant attacking display, Raphinha and Fermín led the team with a brace each, joined by Adeyemi opening his account as a Barça scorer. A standout cameo from debutant Gordon in just 20 minutes put the finishing touch on an imposing start.
José Mourinho has spoken out after the controversial incidents in Cornellá. The Real Madrid coach publicly defended the Brazilian attacker, taking command within the Madrid dressing room and trying to ease the external pressure once again closing in on his biggest star.
He came, he saw, he conquered. Ferran Torres enjoyed a dream start in Ligue 1, rescuing PSG from the brink against Rennes. After trailing 0-2 at half-time, the Spanish forward took control in an extraordinary second half and scored a crucial brace to level the match.
#lvarez
10 hours ago
This story was originally published on CRE Daily. Join 70,000+ commercial real estate professionals getting daily news, market insights, and industry ****** ysis delivered straight to their inbox with the free CRE Daily newsletter.
P&G's Gillette closed on the 232 A Street development in South Boston for $99.29M, taking over the full site.
Breakthrough Properties paid $80M for the property in 2021 and won approval for a 325,000 SF campus.
Boston is one of four core markets that drove nearly 8M SF of life science absorption, per JLL.
P&G's Gillette has closed on the 232 A Street development in South Boston, reports Globe St. It paid $99.29M to Breakthrough Properties. The razor maker first planned a headquarters and Technical Innovation Center on the site's former parking lot. It has now taken over the entire development and pledged to invest close to $1B.
#daily #closed #paid
P&G's Gillette closed on the 232 A Street development in South Boston for $99.29M, taking over the full site.
Breakthrough Properties paid $80M for the property in 2021 and won approval for a 325,000 SF campus.
Boston is one of four core markets that drove nearly 8M SF of life science absorption, per JLL.
P&G's Gillette has closed on the 232 A Street development in South Boston, reports Globe St. It paid $99.29M to Breakthrough Properties. The razor maker first planned a headquarters and Technical Innovation Center on the site's former parking lot. It has now taken over the entire development and pledged to invest close to $1B.
#daily #closed #paid
1 day ago
According to one report which emerged on Sunday morning, Liverpool may be at risk of missing out on Bradley Barcola to a direct Premier League rival in the final few days of the summer transfer window.
The Paris Saint-Germain winger has been the Reds' main target over the past couple of months and has already agreed personal terms on a prospective move to Anfield, although the two clubs have yet to agree a fee for the 23-year-old.
French reporter Fabrice Hawkins claimed last week that 'everyone involved' in the proposed transaction 'thinks there will be an agreement' which'd pave the way for the forward to become an LFC player, although one source has now warned of a threat from within the English top flight.
As reported by CaughtOffside this morning, **** nal could re-enter the race for Barcola amid an impasse between Liverpool and PSG over a price for the winger, with the Reds viewing his maximum worth at £120m but the European champions demanding £130m up front plus a potential £15m in add-ons.
The Gunners are reportedly being kept informed of developments regarding the France international, who it's claimed could be 'tempted' by a move to north London despite already signalling his approval of a switch to Merseyside.
#Liverpool #barcola #move #according
The Paris Saint-Germain winger has been the Reds' main target over the past couple of months and has already agreed personal terms on a prospective move to Anfield, although the two clubs have yet to agree a fee for the 23-year-old.
French reporter Fabrice Hawkins claimed last week that 'everyone involved' in the proposed transaction 'thinks there will be an agreement' which'd pave the way for the forward to become an LFC player, although one source has now warned of a threat from within the English top flight.
As reported by CaughtOffside this morning, **** nal could re-enter the race for Barcola amid an impasse between Liverpool and PSG over a price for the winger, with the Reds viewing his maximum worth at £120m but the European champions demanding £130m up front plus a potential £15m in add-ons.
The Gunners are reportedly being kept informed of developments regarding the France international, who it's claimed could be 'tempted' by a move to north London despite already signalling his approval of a switch to Merseyside.
#Liverpool #barcola #move #according
1 day ago
Former Tampa Bay Buccaneers head coach Jon Gruden made his return to the broadcast booth on Saturday night. The Buccaneers hosted the Kansas City Chiefs in a preseason matchup, with Gruden joining the booth for the home team's WFLA-TV broadcast.
The former football coach and longtime media personality's return to a broadcast booth was met with widespread approval over the weekend.
Gruden spent nearly a decade in ESPN's Monday Night Football booth and became one of the network's most recognizable and popular football broadcasters. His latest appearance represented his first major live booth ****** ignment since leaving ESPN's MNF after the 2017 season to return to the sidelines as the Oakland Raiders' head coach.
NFL fans quickly embraced Gruden's return to the commentary booth during the Bucs-Chiefs preseason broadcast.
"Jon Gruden needs to get back in the booth," one fan wrote.
#Football #night
The former football coach and longtime media personality's return to a broadcast booth was met with widespread approval over the weekend.
Gruden spent nearly a decade in ESPN's Monday Night Football booth and became one of the network's most recognizable and popular football broadcasters. His latest appearance represented his first major live booth ****** ignment since leaving ESPN's MNF after the 2017 season to return to the sidelines as the Oakland Raiders' head coach.
NFL fans quickly embraced Gruden's return to the commentary booth during the Bucs-Chiefs preseason broadcast.
"Jon Gruden needs to get back in the booth," one fan wrote.
#Football #night
1 day ago
On August 13, Brookfield (NYSE:BN) held its second-quarter earnings call, and the story management told was less about property spreadsheets and more about power lines and reactors. Distributable earnings before realizations climbed 15% year over year to $1.4 billion for the quarter, and executives spent much of the call explaining how a $100 billion Kentucky data center project and a nuclear buildout fit into that growth.
Brookfield's pitch centers on a gap between AI's appetite for electricity and the grid's ability to supply it. CEO Bruce Flatt described a $100 billion partnership with the US Department of Energy to build an AI campus in Kentucky on federally owned land, a deal he said requires few approvals because of that federal ownership. Alongside that, the Department of Energy committed a further $17.5 billion to Brookfield and its utility partners to acquire long lead time items for Westinghouse's reactor pipeline, which the company says is now under construction on 14 reactors with visibility into 40 more and another 100 beyond that.
The ****** et management engine backing these bets had its own strong quarter. Fundraising hit a record $77 billion, pushing fee-bearing capital up 19% to $672 billion and fee-related earnings up 20% from a year earlier. The Oaktree acquisition closed in July, and Wealth Solutions distributable earnings rose 23% year over year to $480 million as the newly acquired Just Group added $45 billion of insurance ****** ets. Real estate leasing added another data point: office tenants signed 4.5 million square feet globally at net rents 19% above what was expiring, including leases in Canada priced more than double prior rates.
Flatt opened his remarks by naming the risks directly, pointing to geopolitical conflict, higher energy prices and uncertainty around interest rates as factors shaping the near-term market environment. That acknowledgment sits alongside a Just Group integration that is still a work in progress. Management said it exited an early-stage direct-to-consumer initiative and is still working through reducing the business's cost base, and Just contributed just $29 million of earnings in its first quarter under Brookfield ownership, a starting return on equity of about 12%.
Capital return also raises questions for income-focused shareholders. The board declared a quarterly dividend of only $0.07 per share, while the company spent roughly $580 million on buybacks year to date at an average price of $42, showing where management prefers to direct spare cash. Separately, the approved simplification of Brookfield's capital structure requires taxable Canadian and UK shareholders to actively file an election if they want a tax-deferred share exchange, an administrative step that falls on investors rather than the company. Management also acknowledged the annuity business operates in a competitive market, even as it held spreads above 200 basis points.
#energy #company
Brookfield's pitch centers on a gap between AI's appetite for electricity and the grid's ability to supply it. CEO Bruce Flatt described a $100 billion partnership with the US Department of Energy to build an AI campus in Kentucky on federally owned land, a deal he said requires few approvals because of that federal ownership. Alongside that, the Department of Energy committed a further $17.5 billion to Brookfield and its utility partners to acquire long lead time items for Westinghouse's reactor pipeline, which the company says is now under construction on 14 reactors with visibility into 40 more and another 100 beyond that.
The ****** et management engine backing these bets had its own strong quarter. Fundraising hit a record $77 billion, pushing fee-bearing capital up 19% to $672 billion and fee-related earnings up 20% from a year earlier. The Oaktree acquisition closed in July, and Wealth Solutions distributable earnings rose 23% year over year to $480 million as the newly acquired Just Group added $45 billion of insurance ****** ets. Real estate leasing added another data point: office tenants signed 4.5 million square feet globally at net rents 19% above what was expiring, including leases in Canada priced more than double prior rates.
Flatt opened his remarks by naming the risks directly, pointing to geopolitical conflict, higher energy prices and uncertainty around interest rates as factors shaping the near-term market environment. That acknowledgment sits alongside a Just Group integration that is still a work in progress. Management said it exited an early-stage direct-to-consumer initiative and is still working through reducing the business's cost base, and Just contributed just $29 million of earnings in its first quarter under Brookfield ownership, a starting return on equity of about 12%.
Capital return also raises questions for income-focused shareholders. The board declared a quarterly dividend of only $0.07 per share, while the company spent roughly $580 million on buybacks year to date at an average price of $42, showing where management prefers to direct spare cash. Separately, the approved simplification of Brookfield's capital structure requires taxable Canadian and UK shareholders to actively file an election if they want a tax-deferred share exchange, an administrative step that falls on investors rather than the company. Management also acknowledged the annuity business operates in a competitive market, even as it held spreads above 200 basis points.
#energy #company
1 day ago
On August 13, Ascendis Pharma (NASDAQ:ASND) reported second-quarter results that showed how far its rare disease portfolio has come. Total product revenue roughly doubled from a year earlier to €315 million, and for the first time all three of the company's approved TransCon therapies, SKYTROFA, YORVIPATH and YUVIWEL, were contributing meaningful sales in the same quarter. That combination is what management is leaning on to justify its 2030 revenue ambitions.
YORVIPATH, the hypoparathyroidism treatment, generated €252 million in the quarter and crossed blockbuster level on an annualized basis just two years after its U.S. launch, while reaching patients in more than 35 countries through either commercial sales or named patient access programs. Long-term trial data presented during the quarter showed response rates sustained between 82% and 86% on the combined endpoint, with patients still on therapy at a 95% rate five years after starting.
SKYTROFA, the once-weekly growth hormone therapy, crossed 20,000 unique patient enrollments and remains the best-selling long-acting growth hormone in the US as measured by brand value, contributing €55 million for the quarter. YUVIWEL, the newest of the three, launched commercially in the US during the quarter and brought in €8 million in its first quarter on the market. Enrollment kept climbing after the quarter closed, from more than 170 unique patients through June 30 to more than 220 by the end of July, with more than 65% of those patients already approved for reimbursement. Ascendis also ended the quarter with €812 million in cash and carries no bank debt or convertible debt, giving it room to keep funding these launches without outside financing.
The growth came with a steeper cost base. SG&A expenses rose to €173 million in the quarter from €145 million in the prior quarter, and R&D expenses climbed to €76 million from €59 million, a comparison made sharper by the fact that the prior quarter's figure had been reduced by a one-time €11 million reversal of earlier inventory write-downs. Reported operating profit of €220 million also leaned heavily on a one-time item, a €158 million gain tied to the sale of a PRV. Strip that out and non-IFRS operating profit was €92 million, a 27% margin that better reflects the underlying business. Total revenue of €339 million for the quarter also included €24 million of non-product collaboration revenue, including a €17 million milestone payment tied to TransCon CNP, money that will not repeat every quarter. And while YUVIWEL's early numbers are strong, formal regulatory decisions for the drug in the U.S. and European Union are not expected until the fourth quarter of 2026, meaning current sales are happening ahead of full approval.
#patients #time #transcon
YORVIPATH, the hypoparathyroidism treatment, generated €252 million in the quarter and crossed blockbuster level on an annualized basis just two years after its U.S. launch, while reaching patients in more than 35 countries through either commercial sales or named patient access programs. Long-term trial data presented during the quarter showed response rates sustained between 82% and 86% on the combined endpoint, with patients still on therapy at a 95% rate five years after starting.
SKYTROFA, the once-weekly growth hormone therapy, crossed 20,000 unique patient enrollments and remains the best-selling long-acting growth hormone in the US as measured by brand value, contributing €55 million for the quarter. YUVIWEL, the newest of the three, launched commercially in the US during the quarter and brought in €8 million in its first quarter on the market. Enrollment kept climbing after the quarter closed, from more than 170 unique patients through June 30 to more than 220 by the end of July, with more than 65% of those patients already approved for reimbursement. Ascendis also ended the quarter with €812 million in cash and carries no bank debt or convertible debt, giving it room to keep funding these launches without outside financing.
The growth came with a steeper cost base. SG&A expenses rose to €173 million in the quarter from €145 million in the prior quarter, and R&D expenses climbed to €76 million from €59 million, a comparison made sharper by the fact that the prior quarter's figure had been reduced by a one-time €11 million reversal of earlier inventory write-downs. Reported operating profit of €220 million also leaned heavily on a one-time item, a €158 million gain tied to the sale of a PRV. Strip that out and non-IFRS operating profit was €92 million, a 27% margin that better reflects the underlying business. Total revenue of €339 million for the quarter also included €24 million of non-product collaboration revenue, including a €17 million milestone payment tied to TransCon CNP, money that will not repeat every quarter. And while YUVIWEL's early numbers are strong, formal regulatory decisions for the drug in the U.S. and European Union are not expected until the fourth quarter of 2026, meaning current sales are happening ahead of full approval.
#patients #time #transcon
1 day ago
Tesla (NASDAQ:TSLA), the leading global electric vehicle (EV) and energy storage manufacturer closed at $362.86, up 5.14%. Investors were encouraged by Nevada's permitting of paid robotaxi service as they watched the autonomous ride-hailing rollout progress.
Trading volume reached 58.5 million shares, coming in about 39% above its three-month average of 42.1 million shares. Tesla IPO'd in 2010 and has grown 22,721% since going public.
The S&P 500 (SNPINDEX:^GSPC) closed at 7,674, up 0.43%, while the Nasdaq Composite (NASDAQINDEX:^IXIC) closed at 26,180, also up 0.43%. Among automotive and EV peers, Rivian Automotive (NASDAQ:RIVN) closed at $16.97, up 6.00%, and Ford Motor (NYSE:F) closed at $14.41, up 3.00%, with Tesla drawing extra attention thanks to robotaxi approvals.
Officials announced on Friday that the Nevada Transportation Authority has authorized three autonomous vehicle companies to offer passenger transportation using driverless cars within Clark County, which includes Las Vegas. Tesla has been permitted to operate a fleet of up to 5,000 fully autonomous vehicles in its first year, though it's unlikely the company will deploy that many.
Last week, reports said Tesla was preparing to launch its Cybercab in Austin later this month, beginning with rides for employees. Investors have been anticipating Tesla's fully autonomous ride-hailing fleet, and the stock is reacting to that progress.
In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. If you'd invested $5,000 then, you'd be sitting on $2,815,676 today.*
#investors #robotaxi
Trading volume reached 58.5 million shares, coming in about 39% above its three-month average of 42.1 million shares. Tesla IPO'd in 2010 and has grown 22,721% since going public.
The S&P 500 (SNPINDEX:^GSPC) closed at 7,674, up 0.43%, while the Nasdaq Composite (NASDAQINDEX:^IXIC) closed at 26,180, also up 0.43%. Among automotive and EV peers, Rivian Automotive (NASDAQ:RIVN) closed at $16.97, up 6.00%, and Ford Motor (NYSE:F) closed at $14.41, up 3.00%, with Tesla drawing extra attention thanks to robotaxi approvals.
Officials announced on Friday that the Nevada Transportation Authority has authorized three autonomous vehicle companies to offer passenger transportation using driverless cars within Clark County, which includes Las Vegas. Tesla has been permitted to operate a fleet of up to 5,000 fully autonomous vehicles in its first year, though it's unlikely the company will deploy that many.
Last week, reports said Tesla was preparing to launch its Cybercab in Austin later this month, beginning with rides for employees. Investors have been anticipating Tesla's fully autonomous ride-hailing fleet, and the stock is reacting to that progress.
In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. If you'd invested $5,000 then, you'd be sitting on $2,815,676 today.*
#investors #robotaxi
1 day ago
On August 13, Karyopharm Therapeutics (NASDAQ:KPTI) held its second-quarter earnings call, and the story split cleanly in two. The company laid out a myelofibrosis combination therapy with data strong enough to earn an accelerated approval pathway from the FDA, alongside a cash position that funds operations only into September. A $15.8 million loan payment lands September 10, and management admitted that paying it without new financing could trip a liquidity covenant and trigger default. Investors are being asked to weigh a genuinely differentiated drug against a genuinely short clock.
The bull case rests on selinexor paired with ruxolitinib, which Karyopharm plans to submit for FDA review this month under the Accelerated Approval Pathway for myelofibrosis. The Phase III SENTRY study found statistically significant, rapid, deep, and sustained spleen volume reductions, along with a preliminary overall survival signal and hints of disease modification. At week 24, the combination nearly doubled the spleen response rate versus ruxolitinib alone, with responses showing up as early as week 12 and holding through week 36 across patient subgroups. Even when ruxolitinib was dosed below 15 milligrams a day, the combination produced SVR35 rates as high as 50%, compared with zero for ruxolitinib alone, suggesting doctors could trim ruxolitinib without losing efficacy.
The overall survival hazard ratio at the time of the topline ******* ysis was 0.43. If cleared, this would be the first approved combination therapy in frontline myelofibrosis, a disease affecting roughly 20,000 people in the US with about 4,000 newly treated each year and no combination option on the market. Karyopharm pegs the peak US revenue opportunity at up to $1 billion and plans to lean on the commercial infrastructure it already runs for XPOVIO, including its KaryForward patient support program, to move quickly if approved. On the existing business, XPOVIO generated $30.8 million in U.S. net product revenue in the quarter, with demand holding roughly flat from a year earlier even as the treatment landscape gets more crowded.
The financial picture is where the caution belongs. Total revenue fell to $33.4 million from $37.9 million a year earlier, largely because Menarini's reimbursement of development costs ended in late 2025, a roughly $6.5 million swing. Net loss widened to $67 million from $37.3 million, and while some of that reflects non-cash mark-to-market adjustments tied to the company's financing structure, the cash balance tells its own story: $65.4 million in cash, equivalents, and investments at quarter end. Management said that funds current plans only through September 2026. A $15.8 million term loan payment is due September 10, and if it goes out without additional financing or a lender waiver, cash would fall below the $10 million minimum liquidity covenant, an event of default.
#september #cash #karyopharm #myelofibrosis
The bull case rests on selinexor paired with ruxolitinib, which Karyopharm plans to submit for FDA review this month under the Accelerated Approval Pathway for myelofibrosis. The Phase III SENTRY study found statistically significant, rapid, deep, and sustained spleen volume reductions, along with a preliminary overall survival signal and hints of disease modification. At week 24, the combination nearly doubled the spleen response rate versus ruxolitinib alone, with responses showing up as early as week 12 and holding through week 36 across patient subgroups. Even when ruxolitinib was dosed below 15 milligrams a day, the combination produced SVR35 rates as high as 50%, compared with zero for ruxolitinib alone, suggesting doctors could trim ruxolitinib without losing efficacy.
The overall survival hazard ratio at the time of the topline ******* ysis was 0.43. If cleared, this would be the first approved combination therapy in frontline myelofibrosis, a disease affecting roughly 20,000 people in the US with about 4,000 newly treated each year and no combination option on the market. Karyopharm pegs the peak US revenue opportunity at up to $1 billion and plans to lean on the commercial infrastructure it already runs for XPOVIO, including its KaryForward patient support program, to move quickly if approved. On the existing business, XPOVIO generated $30.8 million in U.S. net product revenue in the quarter, with demand holding roughly flat from a year earlier even as the treatment landscape gets more crowded.
The financial picture is where the caution belongs. Total revenue fell to $33.4 million from $37.9 million a year earlier, largely because Menarini's reimbursement of development costs ended in late 2025, a roughly $6.5 million swing. Net loss widened to $67 million from $37.3 million, and while some of that reflects non-cash mark-to-market adjustments tied to the company's financing structure, the cash balance tells its own story: $65.4 million in cash, equivalents, and investments at quarter end. Management said that funds current plans only through September 2026. A $15.8 million term loan payment is due September 10, and if it goes out without additional financing or a lender waiver, cash would fall below the $10 million minimum liquidity covenant, an event of default.
#september #cash #karyopharm #myelofibrosis
1 day ago
Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billion U.S. investment pledge.
On the very same day, British regulators cleared Eli Lilly and Company (NYSE:LLY)'s weight-loss pill Foundayo for both weight management and type 2 diabetes, making the UK the first country in Europe to approve the drug.
Bristol-Myers Squibb Company (NYSE:BMY)'s new Houston campus, roughly 600,000 square feet, will churn out everything from small-molecule medicines to more complex biologics and antibody-drug conjugates. It is expected to create close to 500 skilled jobs and about 2,000 construction jobs between 2027 and 2030. CEO Christopher Boerner framed it as a vote of confidence in America's biopharma future. The timing lines up with a broader industry trend: drugmakers from Lilly to Johnson & Johnson to Pfizer are all racing to build more in the U.S. as tariff pressure from the Trump administration ramps up.
Eli Lilly took the opposite direction this week, expanding outward instead of inward. Foundayo's UK approval opens a major new market, even though the pill isn't covered by the National Health Service yet and still trails Novo Nordisk's Wegovy pill there.
So which strategy actually serves shareholders better, building strength at home or chasing growth abroad?
#NYSE #myers #squibb #confidence
On the very same day, British regulators cleared Eli Lilly and Company (NYSE:LLY)'s weight-loss pill Foundayo for both weight management and type 2 diabetes, making the UK the first country in Europe to approve the drug.
Bristol-Myers Squibb Company (NYSE:BMY)'s new Houston campus, roughly 600,000 square feet, will churn out everything from small-molecule medicines to more complex biologics and antibody-drug conjugates. It is expected to create close to 500 skilled jobs and about 2,000 construction jobs between 2027 and 2030. CEO Christopher Boerner framed it as a vote of confidence in America's biopharma future. The timing lines up with a broader industry trend: drugmakers from Lilly to Johnson & Johnson to Pfizer are all racing to build more in the U.S. as tariff pressure from the Trump administration ramps up.
Eli Lilly took the opposite direction this week, expanding outward instead of inward. Foundayo's UK approval opens a major new market, even though the pill isn't covered by the National Health Service yet and still trails Novo Nordisk's Wegovy pill there.
So which strategy actually serves shareholders better, building strength at home or chasing growth abroad?
#NYSE #myers #squibb #confidence
1 day ago
Bitcoin (BTC) has gone up by more than 8% in the past 24 hours and has rallied from $62,000 to $77,000 in just 5 days after a series of developments triggered a massive short squeeze across the crypto market.
Short liquidations in the past 24 hours alone surged to $1.2 billion and are now amounting to more than $4.4 billion, most of which came from blown-up BTC shorts.
The U.S. Securities and Exchange Commission (SEC) announced a couple of days ago a series of rules for the crypto market that front-run the approval of the Clarity Act. This move reassured the market that the current administration will do its best to support the sector's growth.
Moreover, President Donald Trump met with crypto executives at the White House and reiterated his commitment to push this key piece of legislation until it makes its way to his desk — ideally, this year.
Market participants reacted quite positively and fully ignored yesterday's hawkish comments found in the last FOMC minutes.
#market #Crypto #securities
Short liquidations in the past 24 hours alone surged to $1.2 billion and are now amounting to more than $4.4 billion, most of which came from blown-up BTC shorts.
The U.S. Securities and Exchange Commission (SEC) announced a couple of days ago a series of rules for the crypto market that front-run the approval of the Clarity Act. This move reassured the market that the current administration will do its best to support the sector's growth.
Moreover, President Donald Trump met with crypto executives at the White House and reiterated his commitment to push this key piece of legislation until it makes its way to his desk — ideally, this year.
Market participants reacted quite positively and fully ignored yesterday's hawkish comments found in the last FOMC minutes.
#market #Crypto #securities
2 days ago
Our ****** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
New Delhi received 29 foreign direct investment proposals worth $500 million with one move: It decided to auto-approve investors from neighboring countries, like China, to hold non-controlling stakes of up to 10%.
India's commerce and industry ministry said the 29 approved proposals, worth 48.95 billion rupees or about $511 million, span across a range of industries including information technology, artificial intelligence, manufacturing, pharmaceuticals, data centers and transport services.
A government decision in May allowed an automatic-approval route for investors from land-bordering countries holding non-controlling stakes of up to 10%.
Previously, any investment tied to a beneficial owner in a bordering nation, a rule aimed squarely at China after the 2020 border clashes, required full government sign-off, regardless of stake size.
#worth #million #countries #controlling
New Delhi received 29 foreign direct investment proposals worth $500 million with one move: It decided to auto-approve investors from neighboring countries, like China, to hold non-controlling stakes of up to 10%.
India's commerce and industry ministry said the 29 approved proposals, worth 48.95 billion rupees or about $511 million, span across a range of industries including information technology, artificial intelligence, manufacturing, pharmaceuticals, data centers and transport services.
A government decision in May allowed an automatic-approval route for investors from land-bordering countries holding non-controlling stakes of up to 10%.
Previously, any investment tied to a beneficial owner in a bordering nation, a rule aimed squarely at China after the 2020 border clashes, required full government sign-off, regardless of stake size.
#worth #million #countries #controlling
2 days ago
Costco is known as the place to go when you want bulk paper towels, produce, and snacks at a reasonable price.
But anyone who pays for a Costco membership knows that the company offers a lot more than just giant packages of household goods and food staples.
The warehouse club has steadily built a much broader business around its members, offering everything from gasoline to travel to optical services.
Now, Costco is taking another major step into an area that could become increasingly important as its customer base ages — health insurance.
The retailer is partnering with nonprofit insurer SCAN Health Plan to offer Costco-branded Medicare Advantage plans in two states, along with a Medicare supplement plan in a third state, pending regulatory approval.
#medicare #scan #known #bulk
But anyone who pays for a Costco membership knows that the company offers a lot more than just giant packages of household goods and food staples.
The warehouse club has steadily built a much broader business around its members, offering everything from gasoline to travel to optical services.
Now, Costco is taking another major step into an area that could become increasingly important as its customer base ages — health insurance.
The retailer is partnering with nonprofit insurer SCAN Health Plan to offer Costco-branded Medicare Advantage plans in two states, along with a Medicare supplement plan in a third state, pending regulatory approval.
#medicare #scan #known #bulk
2 days ago
Branden Jenkins was out to dinner when he pulled out his phone, glanced at his AI usage dashboard, and realized his weekend coding session had just cost him $1,000 — charged automatically, in $1,000 increments, to a card set on auto-renew.
Jenkins is the CEO of Maxio, a private-equity-backed software company headquartered in Atlanta that's on a path toward $100 million in annual revenue over the next couple of years. He's also, by his own admission, near the top of his company's internal AI spending leaderboard — an odd place for the chief executive to land. "A thousand is not that much, I would say, but for one weekend, it's pretty annoying," he said in an interview with Fortune. Describing his agent as "cooking away," he described his response as "Wow, I just got here quickly."
The episode has become something of a parable inside his company — and inside corporate America more broadly — for how quickly "agentic" AI tools can consume money without anyone quite noticing until the bill lands. But Jenkins said the surprise invoice isn't what's keeping him up at night. The deeper problem is something messier and more human: his own employees' "insecurity" about being outpaced by the technology — and by him.
Jenkins, a self-described technical CEO who builds his own agents and automations, said he can write code from his phone using Claude even while away from his desk — which is how he ended up debugging and iterating on a project at dinner. The token wallet he'd set up to fund those sessions was configured to auto-refill by $1,000 every time it ran dry, silently recharging his card without requiring a second thought — until he saw the total.
"I don't have governors where a lot of my staff hits limits, and they have to ask for approval," Jenkins said, describing his own unlimited internal budget as both a perk and a liability. "So I started leaning in and going, 'What does this look like?'"
#auto
Jenkins is the CEO of Maxio, a private-equity-backed software company headquartered in Atlanta that's on a path toward $100 million in annual revenue over the next couple of years. He's also, by his own admission, near the top of his company's internal AI spending leaderboard — an odd place for the chief executive to land. "A thousand is not that much, I would say, but for one weekend, it's pretty annoying," he said in an interview with Fortune. Describing his agent as "cooking away," he described his response as "Wow, I just got here quickly."
The episode has become something of a parable inside his company — and inside corporate America more broadly — for how quickly "agentic" AI tools can consume money without anyone quite noticing until the bill lands. But Jenkins said the surprise invoice isn't what's keeping him up at night. The deeper problem is something messier and more human: his own employees' "insecurity" about being outpaced by the technology — and by him.
Jenkins, a self-described technical CEO who builds his own agents and automations, said he can write code from his phone using Claude even while away from his desk — which is how he ended up debugging and iterating on a project at dinner. The token wallet he'd set up to fund those sessions was configured to auto-refill by $1,000 every time it ran dry, silently recharging his card without requiring a second thought — until he saw the total.
"I don't have governors where a lot of my staff hits limits, and they have to ask for approval," Jenkins said, describing his own unlimited internal budget as both a perk and a liability. "So I started leaning in and going, 'What does this look like?'"
#auto
2 days ago
A divided federal appeals court ruled that the Trump-picked US Attorney in Albany is serving unlawfully and can no longer be involved in the investigation of one of the president's top foes.
The Second Circuit Court of Appeals, in a 2-1 decision, upheld a lower court's ruling from January that said the appointment of John Sarcone, then-Acting US attorney for the Northern District of New York, is not valid and disqualified him from a probe into the state's Attorney General Letitia James.
The decision marks the third time a federal appeals court has rejected as unlawful the Trump administration's process for naming US attorneys without Senate approval.
"We disagree with the court's decision, and intend to take this case to the Supreme Court," the Justice Department wrote in a tweet Friday.
Earlier this week, the Ninth Circuit Court of Appeals said the US attorney for Nevada, Sigal Chattah, is serving unlawfully. The Justice Department said it would appeal to the Supreme Court. In December the Third Circuit ruled that Alina Habba was not validly appointed US attorney for New Jersey.
#appeals #department
The Second Circuit Court of Appeals, in a 2-1 decision, upheld a lower court's ruling from January that said the appointment of John Sarcone, then-Acting US attorney for the Northern District of New York, is not valid and disqualified him from a probe into the state's Attorney General Letitia James.
The decision marks the third time a federal appeals court has rejected as unlawful the Trump administration's process for naming US attorneys without Senate approval.
"We disagree with the court's decision, and intend to take this case to the Supreme Court," the Justice Department wrote in a tweet Friday.
Earlier this week, the Ninth Circuit Court of Appeals said the US attorney for Nevada, Sigal Chattah, is serving unlawfully. The Justice Department said it would appeal to the Supreme Court. In December the Third Circuit ruled that Alina Habba was not validly appointed US attorney for New Jersey.
#appeals #department
3 days ago
U.S. shale billionaire Harold Hamm is making a multibillion-dollar bet on Argentina's Vaca Muerta, becoming the latest high-profile American investor to target the rapidly expanding shale basin.
Hamm's Continental Resources has agreed to acquire a 50% interest in Phoenix Global Resources, creating an equal joint venture with commodities giant Mercuria Energy Group. The partners plan to invest more than $4 billion over five years and increase Phoenix's production from more than 28,000 barrels of oil equivalent per day to over 100,000 boed.
The combined portfolio will encompass approximately 163,000 net acres across six Vaca Muerta blocks. The proposed transaction remains subject to definitive agreements, closing conditions and regulatory approvals.
Continental is no stranger to the formation. The company entered Argentina last year by acquiring **** ets from Pluspetrol and subsequently bought interests in blocks operated by Pan American Energy. CEO Doug Lawler credited President Javier Milei's economic reforms with helping create the conditions for Continental's latest investment.
Hamm isn't the only American billionaire taking an interest.
#american #continental #shale #latest
Hamm's Continental Resources has agreed to acquire a 50% interest in Phoenix Global Resources, creating an equal joint venture with commodities giant Mercuria Energy Group. The partners plan to invest more than $4 billion over five years and increase Phoenix's production from more than 28,000 barrels of oil equivalent per day to over 100,000 boed.
The combined portfolio will encompass approximately 163,000 net acres across six Vaca Muerta blocks. The proposed transaction remains subject to definitive agreements, closing conditions and regulatory approvals.
Continental is no stranger to the formation. The company entered Argentina last year by acquiring **** ets from Pluspetrol and subsequently bought interests in blocks operated by Pan American Energy. CEO Doug Lawler credited President Javier Milei's economic reforms with helping create the conditions for Continental's latest investment.
Hamm isn't the only American billionaire taking an interest.
#american #continental #shale #latest
3 days ago
Ukrainian club Shakhtar Donetsk have agreed to play Champions League home games at Chelsea's Stamford Bridge this season.
It means that west London will host at least four fixtures in the expanded league phase of the competition, with the draw to come next Thursday.
However, it remains subject to regulatory approval but Uefa, European football's governing body, and Hammersmith and Fulham Council have signed the move off.
Upon announcing the agreement, which is understood to be non-commercial, Chelsea said: "FC Shakhtar have played in countries across Europe and we look forward to welcoming them to London for their Champions League campaign this year.
"We will be working with the Shakhtar team closely over the coming weeks to ensure that matchdays run safely and smoothly for their team and supporters."
#london #ukrainian
It means that west London will host at least four fixtures in the expanded league phase of the competition, with the draw to come next Thursday.
However, it remains subject to regulatory approval but Uefa, European football's governing body, and Hammersmith and Fulham Council have signed the move off.
Upon announcing the agreement, which is understood to be non-commercial, Chelsea said: "FC Shakhtar have played in countries across Europe and we look forward to welcoming them to London for their Champions League campaign this year.
"We will be working with the Shakhtar team closely over the coming weeks to ensure that matchdays run safely and smoothly for their team and supporters."
#london #ukrainian
3 days ago
On August 13, Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter results that captured a company scaling a genuinely new kind of medicine while working through the ***** ps that come with it. ZEVASKYN, its cell therapy for a severe skin disease called recessive dystrophic epidermolysis bullosa, brought in $11.4 million in revenue for the quarter, and the number of patients treated kept rising. But the call also laid out cancellations, manufacturing hiccups, and a shift in how the company plans to report its own progress, all within the same three months.
Revenue climbed 31%, or $2.7 million, to $11.4 million from $8.7 million in the first quarter of 2026. Abeona has now treated 12 patients since ZEVASKYN's launch, including five in the second quarter and three more in the third quarter to date. The treatment center network grew alongside that, reaching seven activated sites with the recent addition of Cincinnati Children's, one of the largest epidermolysis bullosa treatment hubs in the country. New York-Presbyterian/Columbia University Irving Medical Center and Children's Hospital of Philadelphia also came online during the quarter, and CHOP moved fast, completing its first treatment in July just months after activating in May. UTMB, meanwhile, finished its first patient biopsy. Roughly 40% of the addressable patient population now has in-state access to a qualified treatment center.
Abeona also picked up a new technology add-on payment from the Centers for Medicare and Medicaid Services, effective Oct. 1, 2026, for fiscal year 2027, making it one of only three approvals out of 15 new applications that cycle. On the cost side, R&D spending fell to $5 million from $9.6 million, which had included a one-time $7 million licensing payment, and SG&A dropped to $15.8 million from $19.5 million. The company closed the quarter with $146.8 million in cash and short-term investments.
The net loss widened to $20.2 million, or $0.35 per share, from $17.1 million, or $0.30 per share, in the first quarter. Of the five patients treated in the second quarter, only four generated recognized revenue, because one batch's cell yield came in below the threshold required for recognition. Management pointed to ZEVASKYN's 84-hour shelf life as a core operational challenge, since it forces dermatologists, surgeons, anesthesiologists, and hospital staff to lock in exact dates well ahead of time. That rigidity showed up directly in the numbers: two scheduled biopsies were canceled at the last minute in the second quarter after patients' health unexpectedly declined, and because those slots had been booked so far in advance, they could not be filled by another patient.
#abeona #first #center
Revenue climbed 31%, or $2.7 million, to $11.4 million from $8.7 million in the first quarter of 2026. Abeona has now treated 12 patients since ZEVASKYN's launch, including five in the second quarter and three more in the third quarter to date. The treatment center network grew alongside that, reaching seven activated sites with the recent addition of Cincinnati Children's, one of the largest epidermolysis bullosa treatment hubs in the country. New York-Presbyterian/Columbia University Irving Medical Center and Children's Hospital of Philadelphia also came online during the quarter, and CHOP moved fast, completing its first treatment in July just months after activating in May. UTMB, meanwhile, finished its first patient biopsy. Roughly 40% of the addressable patient population now has in-state access to a qualified treatment center.
Abeona also picked up a new technology add-on payment from the Centers for Medicare and Medicaid Services, effective Oct. 1, 2026, for fiscal year 2027, making it one of only three approvals out of 15 new applications that cycle. On the cost side, R&D spending fell to $5 million from $9.6 million, which had included a one-time $7 million licensing payment, and SG&A dropped to $15.8 million from $19.5 million. The company closed the quarter with $146.8 million in cash and short-term investments.
The net loss widened to $20.2 million, or $0.35 per share, from $17.1 million, or $0.30 per share, in the first quarter. Of the five patients treated in the second quarter, only four generated recognized revenue, because one batch's cell yield came in below the threshold required for recognition. Management pointed to ZEVASKYN's 84-hour shelf life as a core operational challenge, since it forces dermatologists, surgeons, anesthesiologists, and hospital staff to lock in exact dates well ahead of time. That rigidity showed up directly in the numbers: two scheduled biopsies were canceled at the last minute in the second quarter after patients' health unexpectedly declined, and because those slots had been booked so far in advance, they could not be filled by another patient.
#abeona #first #center
3 days ago
The autonomous driving industry is moving rapidly towards commercialization, with competition intensifying as firms race to commercialize robotaxi services both domestically and overseas. China, in particular, is gaining growing recognition as a major player in the autonomous driving race.
Driverless vehicles are becoming a common sight in China, with companies including Baidu, Inc. (NASDAQ: BIDU), WeRide and Pony AI Inc. (NASDAQ:PONY) operating commercial robotaxi services within select areas. The country's self-driving industry stands apart because it builds around a network of companies.
Autonomous vehicles are being made by established carmakers, specialists develop the software, and use the same batteries, sensors, and chips and as electric cars. The government is backing up the initiative through pilot programs, and China's complex traffic environment helps generate vast amounts of data to improve software.
In its latest endeavor, Chinese autonomous driving company Pony.ai has announced a planned and potential overseas robotaxi deployments of more than 4,000 vehicles, aiming to expand beyond China. This macro setup remains favorable for long-term demand, but profitability inherently depends on factors such as regulatory approvals, vehicle economics, and utilization.
A driverless vehicle navigating city traffic, equipped with ADAS and safety features.
#driving #vehicles #industry
Driverless vehicles are becoming a common sight in China, with companies including Baidu, Inc. (NASDAQ: BIDU), WeRide and Pony AI Inc. (NASDAQ:PONY) operating commercial robotaxi services within select areas. The country's self-driving industry stands apart because it builds around a network of companies.
Autonomous vehicles are being made by established carmakers, specialists develop the software, and use the same batteries, sensors, and chips and as electric cars. The government is backing up the initiative through pilot programs, and China's complex traffic environment helps generate vast amounts of data to improve software.
In its latest endeavor, Chinese autonomous driving company Pony.ai has announced a planned and potential overseas robotaxi deployments of more than 4,000 vehicles, aiming to expand beyond China. This macro setup remains favorable for long-term demand, but profitability inherently depends on factors such as regulatory approvals, vehicle economics, and utilization.
A driverless vehicle navigating city traffic, equipped with ADAS and safety features.
#driving #vehicles #industry
3 days ago
Newcastle United are preparing for one of the biggest training ground projects in English football after agreeing to buy the 260-acre Woolsington Hall estate for a proposed new £190 million performance complex.
According to The Sun, the Magpies want the site, which is close to Newcastle International Airport and around five miles north-west of the city centre, to become the new home of their men's first team and academy.
Subject to planning approval, the Magpies hope to complete the move in time for the 2029/30 season, with a formal application expected to be submitted to Newcastle City Council early next year.
The project will transform the historic estate while keeping its character.
Woolsington Hall includes a listed country house and large areas of parkland, with Newcastle planning to restore and improve the existing buildings and surroundings as part of the development.
#newcastle
According to The Sun, the Magpies want the site, which is close to Newcastle International Airport and around five miles north-west of the city centre, to become the new home of their men's first team and academy.
Subject to planning approval, the Magpies hope to complete the move in time for the 2029/30 season, with a formal application expected to be submitted to Newcastle City Council early next year.
The project will transform the historic estate while keeping its character.
Woolsington Hall includes a listed country house and large areas of parkland, with Newcastle planning to restore and improve the existing buildings and surroundings as part of the development.
#newcastle
3 days ago
Datavault AI Inc. (NASDAQ: $DVLT) has agreed to acquire Wyoming-chartered BankWyse, adding regulated custody and commercial banking capabilities to a tokenization platform that is beginning to show stronger revenue growth.
The deal remains subject to regulatory approval and customary closing conditions. BankWyse operates as a Wyoming Special Purpose Depository Institution, combining qualified custody with commercial banking services across digital **** ets and fiat currencies.
Datavault said the acquisition would connect banking and custody to a broader stack built around data valuation, tokenization and exchange infrastructure. Customers are expected to be able to bring data and real-world **** ets onto the platform, have those **** ets valued and tokenized, hold them in custody and eventually trade them through Datavault-operated exchanges.
More From Cryptoprowl:
MEXC July TradFi Trading Shifts Toward AI Storage as SNDK Futures Volume Surges More Than 15x Times
#wyoming
The deal remains subject to regulatory approval and customary closing conditions. BankWyse operates as a Wyoming Special Purpose Depository Institution, combining qualified custody with commercial banking services across digital **** ets and fiat currencies.
Datavault said the acquisition would connect banking and custody to a broader stack built around data valuation, tokenization and exchange infrastructure. Customers are expected to be able to bring data and real-world **** ets onto the platform, have those **** ets valued and tokenized, hold them in custody and eventually trade them through Datavault-operated exchanges.
More From Cryptoprowl:
MEXC July TradFi Trading Shifts Toward AI Storage as SNDK Futures Volume Surges More Than 15x Times
#wyoming
3 days ago
Aug 19 (Reuters) - Indian fintech startup Navi said on Wednesday it will raise $100 million from Dutch technology investor Prosus NV in its first institutional funding round, a deal that comes ahead of a planned initial public offering, a source familiar with the matter said.
Reuters could not determine the valuation at which Prosus made the investment. The investment values Navi at about $1.3 billion, the Economic Times reported on Wednesday, citing a person with direct knowledge of the matter.
Navi is seeking a valuation of about $2 billion in the IPO, the source said, declining to be named because the information is confidential. The company did not immediately respond to a request for comment on its IPO plans or valuation.
Navi was founded in 2018 by Sachin Bansal, a co-founder of Walmart-backed Indian e-commerce firm Flipkart. The company offers digital payments, lending, mutual funds and insurance through a digital platform.
The investment is subject to regulatory approvals, including from the Competition Commission of India, Navi said in a statement.
#navi #investment #reuters #matter
Reuters could not determine the valuation at which Prosus made the investment. The investment values Navi at about $1.3 billion, the Economic Times reported on Wednesday, citing a person with direct knowledge of the matter.
Navi is seeking a valuation of about $2 billion in the IPO, the source said, declining to be named because the information is confidential. The company did not immediately respond to a request for comment on its IPO plans or valuation.
Navi was founded in 2018 by Sachin Bansal, a co-founder of Walmart-backed Indian e-commerce firm Flipkart. The company offers digital payments, lending, mutual funds and insurance through a digital platform.
The investment is subject to regulatory approvals, including from the Competition Commission of India, Navi said in a statement.
#navi #investment #reuters #matter
3 days ago
On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once. CEO Claire Mazumdar announced she will step into a Vice Chair and Strategic Adviser role at the start of next year, handing the top job to President and Chief Operating Officer Ryan Cohlhepp. That handoff arrives just as the company points to fresh survival data for ficerafusp alfa, its lead drug candidate for frontline recurrent or metastatic HPV-negative head and neck cancer, and pushes its pivotal trial toward a critical readout.
At May's ASCO meeting, Bicara presented three-year follow-up data spanning roughly 90 patients across three dose cohorts, the longest follow-up reported for any investigational agent in HPV-negative head and neck cancer. At the 1,500 milligram weekly pivotal dose, about one in three patients was still alive at three years, roughly double the survival rate seen in retrospective **** yses of standard-of-care pembrolizumab in this population. Management ties that benefit to the drug's TGF-beta inhibition, which it says drives tumor penetration and immune cell infiltration rather than blocking a single pathway. Overall survival nearly doubled against the standard of care while the safety profile stayed consistent, the company said.
Execution on the pivotal Phase III FORTIFI-HN01 study has kept pace. Bicara says it is on track for substantial enrollment by the end of 2026, with more than 200 sites now active, positioning the trial for a mid-2027 interim readout that could open the door to accelerated approval. The company also launched FORTIFI-FLEX, a study of an every-three-week maintenance dose built on encouraging results from an exploratory every-two-week cohort shown earlier this year, with data targeted for the time of any U.S. approval decision. Beyond the core indication, Bicara points to early proof of concept in cutaneous squamous cell carcinoma and **** canal cancer, backed by roughly $497 million in cash that management says funds operations through the first half of 2029.
The leadership overhaul goes well beyond the CEO chair. Jenn Larson took over as Chief Financial Officer the day after the call, succeeding Ivan Hyep, who had a hand in raising over $800 million for the company since its early days. Two more transitions take effect in January: Chief Development Officer Tanya Green moves into the Chief Operating Officer seat, and Chief Corporate Affairs Officer Jenna Cohen becomes Chief Business Officer. A new Chief Legal Officer and two new board members are joining as well, a lot of change concentrated in a single quarter right as the company approaches its most consequential trial milestone.
#bicara #three #survival #cancer
At May's ASCO meeting, Bicara presented three-year follow-up data spanning roughly 90 patients across three dose cohorts, the longest follow-up reported for any investigational agent in HPV-negative head and neck cancer. At the 1,500 milligram weekly pivotal dose, about one in three patients was still alive at three years, roughly double the survival rate seen in retrospective **** yses of standard-of-care pembrolizumab in this population. Management ties that benefit to the drug's TGF-beta inhibition, which it says drives tumor penetration and immune cell infiltration rather than blocking a single pathway. Overall survival nearly doubled against the standard of care while the safety profile stayed consistent, the company said.
Execution on the pivotal Phase III FORTIFI-HN01 study has kept pace. Bicara says it is on track for substantial enrollment by the end of 2026, with more than 200 sites now active, positioning the trial for a mid-2027 interim readout that could open the door to accelerated approval. The company also launched FORTIFI-FLEX, a study of an every-three-week maintenance dose built on encouraging results from an exploratory every-two-week cohort shown earlier this year, with data targeted for the time of any U.S. approval decision. Beyond the core indication, Bicara points to early proof of concept in cutaneous squamous cell carcinoma and **** canal cancer, backed by roughly $497 million in cash that management says funds operations through the first half of 2029.
The leadership overhaul goes well beyond the CEO chair. Jenn Larson took over as Chief Financial Officer the day after the call, succeeding Ivan Hyep, who had a hand in raising over $800 million for the company since its early days. Two more transitions take effect in January: Chief Development Officer Tanya Green moves into the Chief Operating Officer seat, and Chief Corporate Affairs Officer Jenna Cohen becomes Chief Business Officer. A new Chief Legal Officer and two new board members are joining as well, a lot of change concentrated in a single quarter right as the company approaches its most consequential trial milestone.
#bicara #three #survival #cancer
3 days ago
CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.
Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up the immune system, personalized cancer vaccines train the immune system to specifically target mutations found only on a person's tumor.
Merck and Moderna said on Wednesday their vaccine helped prevent the return and spread of disease in a large trial involving more than 1,000 melanoma patients. They had localized tumors that were removed surgically, but had a high risk of recurrence. Moderna expects that thousands of melanoma patients could benefit within the first few years of approval.
"It is a big deal for the field in general," said Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute. "With this positive study, there is hope (and likely investment to follow) that these approaches may change the way we treat cancer more broadly."
The trial result is "a monumental leap forward," validating mRNA technology as a cancer treatment, said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology.
#cancer #merck #general
Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up the immune system, personalized cancer vaccines train the immune system to specifically target mutations found only on a person's tumor.
Merck and Moderna said on Wednesday their vaccine helped prevent the return and spread of disease in a large trial involving more than 1,000 melanoma patients. They had localized tumors that were removed surgically, but had a high risk of recurrence. Moderna expects that thousands of melanoma patients could benefit within the first few years of approval.
"It is a big deal for the field in general," said Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute. "With this positive study, there is hope (and likely investment to follow) that these approaches may change the way we treat cancer more broadly."
The trial result is "a monumental leap forward," validating mRNA technology as a cancer treatment, said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology.
#cancer #merck #general
3 days ago
Webull rallies 7% into Q2 earnings as ******* ysts project 16% revenue growth, while Vlad Tenev drives Robinhood 7% higher lobbying for tokenized stock approval.
Coinbase surges 11% on Bitcoin's rally but remains down 35% YTD, pulling ARKF up just 4% in a bounce rather than a trend reversal.
Act now: the ******* yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Robinhood didn't make the cut. Grab the names FREE today.
Retail brokerage stocks are rallying midday Wednesday as Bitcoin (CRYPTO:BTC) surges and two separate company stories converge on the same crypto catalyst. Webull (NASDAQ:BULL) shares are up 7% to $8.49 ahead of the company's Q2 2026 earnings report after the close, while Robinhood Markets (NASDAQ:HOOD) shares are climbing 7% to $98.45 as CEO Vlad Tenev pushes U.S. regulators to approve tokenized stocks.
Coinbase (NASDAQ:COIN) shares are up 11% to $163.32, extending a sharp bounce for the largest U.S. crypto exchange. Bitcoin is trading around $68,500, up 6% over the past 24 hours.
#Crypto #webull
Coinbase surges 11% on Bitcoin's rally but remains down 35% YTD, pulling ARKF up just 4% in a bounce rather than a trend reversal.
Act now: the ******* yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Robinhood didn't make the cut. Grab the names FREE today.
Retail brokerage stocks are rallying midday Wednesday as Bitcoin (CRYPTO:BTC) surges and two separate company stories converge on the same crypto catalyst. Webull (NASDAQ:BULL) shares are up 7% to $8.49 ahead of the company's Q2 2026 earnings report after the close, while Robinhood Markets (NASDAQ:HOOD) shares are climbing 7% to $98.45 as CEO Vlad Tenev pushes U.S. regulators to approve tokenized stocks.
Coinbase (NASDAQ:COIN) shares are up 11% to $163.32, extending a sharp bounce for the largest U.S. crypto exchange. Bitcoin is trading around $68,500, up 6% over the past 24 hours.
#Crypto #webull
3 days ago
Datavault AI Inc. (NASDAQ: $DVLT) has agreed to acquire Wyoming-chartered BankWyse, adding regulated custody and commercial banking capabilities to a tokenization platform that is beginning to show stronger revenue growth.
The deal remains subject to regulatory approval and customary closing conditions. BankWyse operates as a Wyoming Special Purpose Depository Institution, combining qualified custody with commercial banking services across digital ******* ets and fiat currencies.
Datavault said the acquisition would connect banking and custody to a broader stack built around data valuation, tokenization and exchange infrastructure. Customers are expected to be able to bring data and real-world ******* ets onto the platform, have those ******* ets valued and tokenized, hold them in custody and eventually trade them through Datavault-operated exchanges.
More From Cryptoprowl:
MEXC July TradFi Trading Shifts Toward AI Storage as SNDK Futures Volume Surges More Than 15x Times
#assets #wyoming #data
The deal remains subject to regulatory approval and customary closing conditions. BankWyse operates as a Wyoming Special Purpose Depository Institution, combining qualified custody with commercial banking services across digital ******* ets and fiat currencies.
Datavault said the acquisition would connect banking and custody to a broader stack built around data valuation, tokenization and exchange infrastructure. Customers are expected to be able to bring data and real-world ******* ets onto the platform, have those ******* ets valued and tokenized, hold them in custody and eventually trade them through Datavault-operated exchanges.
More From Cryptoprowl:
MEXC July TradFi Trading Shifts Toward AI Storage as SNDK Futures Volume Surges More Than 15x Times
#assets #wyoming #data
3 days ago
Aug 19 (Reuters) - Indian fintech startup Navi said on Wednesday it will raise $100 million from Dutch technology investor Prosus NV in its first institutional funding round, a deal that comes ahead of a planned initial public offering, a source familiar with the matter said.
Reuters could not determine the valuation at which Prosus made the investment. The investment values Navi at about $1.3 billion, the Economic Times reported on Wednesday, citing a person with direct knowledge of the matter.
Navi is seeking a valuation of about $2 billion in the IPO, the source said, declining to be named because the information is confidential. The company did not immediately respond to a request for comment on its IPO plans or valuation.
Navi was founded in 2018 by Sachin Bansal, a co-founder of Walmart-backed Indian e-commerce firm Flipkart. The company offers digital payments, lending, mutual funds and insurance through a digital platform.
The investment is subject to regulatory approvals, including from the Competition Commission of India, Navi said in a statement.
#prosus
Reuters could not determine the valuation at which Prosus made the investment. The investment values Navi at about $1.3 billion, the Economic Times reported on Wednesday, citing a person with direct knowledge of the matter.
Navi is seeking a valuation of about $2 billion in the IPO, the source said, declining to be named because the information is confidential. The company did not immediately respond to a request for comment on its IPO plans or valuation.
Navi was founded in 2018 by Sachin Bansal, a co-founder of Walmart-backed Indian e-commerce firm Flipkart. The company offers digital payments, lending, mutual funds and insurance through a digital platform.
The investment is subject to regulatory approvals, including from the Competition Commission of India, Navi said in a statement.
#prosus
